![]() ![]() Intraand interindividual differences were analysed before (0 h n = 115), at 2 - 3 hours after the start of infusional 5-FU treatment (n = 19) (early sampling) and towards the end of the infusion (n = 96) (late sampling). ![]() 5-FU plasma concentrations were measured using an immunolinked Elisa assay (Saladax 5-FU PCM TM). Methods: 230 blood samples were obtained from 31 different gastrointestinal cancer patients (esophagus (8), stomach (10), ileum (1), colorectum (12)) treated with 5-FU-infusional regimes, based on a 24- or 48-hour AIO treatment-schedule. The aim of this study was to analyse the intraand interindividual variability of 5-FU AUC-levels in patients with 5-FU infusion therapy. The optimal concentration-range (AUC, area under the curve) has been described to be within 20 -25 mgh/l. ![]() neutropenia, diarrhea or cardiotoxicity, the knowledge of 5-FU serum levels might help to attribute these side effects to the 5-FU compound. As adverse events are not specific to the 5-FU component of the chemotherapy-combination, i.e. ![]() It is generally well tolerated, but side-effects might require dose-adjustment. Introduction: 5-Fluorouracil (5-FU) is the basis of most combination chemotherapies for gastrointestinal tumors. Keywords: 5-FU Plasma Concentration Immunolinked Elisa Assay Department of Gastroenterology and Endocrinology, University Medicine Göttingen, Göttingen, Germany.Įmail: December 29 th, 2011 revised January 30 th, 2012 accepted February 14 th, 2012 ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |